ORGANIZED BY:
Department of Medical and Surgical Sciences (DIMEC)
Alma Mater Studiorum
University of Bologna, Italy

Division of Renal Diseases and Hypertension
University of Colorado
Anschutz Medical Campus
Aurora-CO, USA

INTERNATIONAL SYMPOSIUM ON:
URIC ACID AND CARDIOMETABOLIC DISEASE: FROM BENCH TO BEDSIDE

BOLOGNA (ITALY)

NOVEMBER 13TH-14TH 2018
After more than a century of active research, uric acid has gained the stage as one of the most reliable candidates for the huge amount of residual cardio-metabolic risk.

The involvement of uric acid in the pathophysiology of hypertension, diabetes and metabolic syndrome, particularly at younger ages, supports the importance of the research in this area.

The interaction between genetics, biochemistry, epidemiology and lifestyle is the engine that has boosted the worldwide interest for uric acid and cardio-metabolic disease.

Now is time to move from academy to clinical practice since we urgently need a reliable tool to identify which patients deserve something more than theory and hypothesis.

The 4th edition of the Bologna meeting will be focused on the patient with the goal to discuss several burning topics:

- Are all the patients with elevated serum uric acid levels the same?
- What is the threshold level for “cardio-metabolic” hyperuricemia?
- How to identify the patients at risk of cardio-metabolic disease?
- What about in children and adolescents?
- What are the differences with cardiovascular complicated gout?
- What are the preventive/therapeutic strategies?
- What is the role of ULT?
- What advantages/harm of the use of non-ULT drugs affecting uric acid?
- What is the current position of Guidelines?
INTERNATIONAL SYMPOSIUM ON:
URIC ACID AND CARDIOMETABOLIC DISEASE: FROM BENCH TO BEDSIDE

WITH THE ENDORSEMENT OF:

PRESIDENT OF THE MEETING:
Claudio Borghi
Department of Medical and Surgical Sciences (DIMEC)
Department of Internal Medicine
Alma Mater Studiorum University of Bologna
St. Orsola-Malpighi University Hospital (Bologna, Italy)

CO-ORGANIZER:
Richard J. Johnson
Division of Renal Diseases and Hypertension, University of Colorado
Anschutz Medical Campus (Aurora-CO, USA)

SCIENTIFIC SECRETARIAT:
Arrigo F.G. Cicero
Alma Mater Studiorum University of Bologna (Bologna, Italy)
Agostino Virdis
University of Pisa (Pisa, Italy)

ORGANIZING SECRETARIAT AND PROVIDER FOR ITALIAN CME ACCREDITATION:
I&C s.r.l.
Via Andrea Costa, 202/6, 40134 Bologna (Italy)
Tel.: +39 051 6144004 - Fax: +39 051 6142772
E-mail: stefania.parolari@iec-srl.it - roberta.loggini@iec-srl.it
Website: www.iec-srl.it

WITH AN UNRESTRICTED GRANT BY:
Fondazione Internazionale Menarini
Centro Direzionale Milanofiori
20089 Rozzano (Milan, Italy) Edificio L – Strada 6
Phone: +39 02 55308110 - Fax: +39 02 55305739
E-mail: milan@fondazione-menarini.it
Website: www.fondazione-menarini.it
### Tuesday, November 13th, 2018 – Morning
Salone del Podestà - Palazzo Re Enzo

#### Session I – The cardio-metabolic burden in patients with gout

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 09.00 a.m. | Introduction to the meeting objectives  
C. Borghi (Bologna, IT) |
| 09.20 a.m. | F. M. Galassi (Adelaide, AU)  
Uric acid and gout: tales from the Ancient World |
| 09.40 a.m. | L. Punzi (Padua, IT)  
The cardio-metabolic involvement in gout. The position of guidelines |
| 10.00 a.m. | D. Rothenbacher (Ulm, DE)  
How can we quantify the cardio-metabolic risk in patients with gout?  
An epidemiological perspective |
| 10.20 a.m. | M. Andrés (Alicante, ES)  
The management of cardio-metabolic risk in patients with gout |
| 10.40 a.m. | M. M. Givertz (Boston-MA, US)  
Treating gout in patients with cardiovascular disease |
| 11.00 a.m. | General discussion |
| 11.30 a.m. | Coffee break |
| 12.00 p.m. | Main Lecture  
*Introduction:*  
E. Ambrosioni (Bologna, IT), M. H. Alderman (New York-NY, US),  
R. J. Johnson (Aurora-CO, US)  
From uric acid to cardio-metabolic disease: can we identify the patients at risk? |
| 01.00 p.m. | Lunch |
### Session II – Update on the Clinical Evidence: Uric Acid and Cardiovascular Disease

**Chairpersons:**
- **P. Palatini** (Padua, IT)
- **J. Redon** (Valencia, ES)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>02.00 p.m.</td>
<td><strong>A. Virdis</strong> (Pisa, IT)</td>
<td>Uric acid and blood pressure</td>
</tr>
<tr>
<td>02.20 p.m.</td>
<td><strong>S. G. Wannamethee</strong> (London, UK)</td>
<td>Uric acid, left ventricular function and heart failure</td>
</tr>
<tr>
<td>02.40 p.m.</td>
<td><strong>C. Borghi</strong> (Bologna, IT)</td>
<td>Uric acid and coronary artery disease</td>
</tr>
<tr>
<td>03.00 p.m.</td>
<td><strong>K. Tsioufis</strong> (Athens, GR)</td>
<td>Uric acid and atrial fibrillation</td>
</tr>
<tr>
<td>03.20 p.m.</td>
<td></td>
<td>General discussion</td>
</tr>
<tr>
<td>03.40 p.m.</td>
<td></td>
<td><strong>Coffee break</strong></td>
</tr>
</tbody>
</table>

### Session III – Update on the Clinical Evidence: Uric Acid, Metabolic and Renal Disease

**Chairpersons:**
- **M. Burnier** (Lausanne, CH)
- **C. Borghi** (Bologna, IT)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>04.10 p.m.</td>
<td><strong>D. H. Kang</strong> (Seoul, KR)</td>
<td>Uric acid and new-onset metabolic syndrome</td>
</tr>
<tr>
<td>04.30 p.m.</td>
<td><strong>M. Kuwabara</strong> (Tokyo, JP)</td>
<td>The interaction between uric acid and lipid profile</td>
</tr>
<tr>
<td>04.50 p.m.</td>
<td><strong>R. Pontremoli</strong> (Genoa, IT)</td>
<td>Uric acid and renal dysfunction: what is the egg?</td>
</tr>
<tr>
<td>05.10 p.m.</td>
<td><strong>R. Cifkova</strong> (Prague, CZ)</td>
<td>Uric acid, pregnancy and cardio-renal disease</td>
</tr>
<tr>
<td>05.30 p.m.</td>
<td></td>
<td>General discussion</td>
</tr>
<tr>
<td>06.00 p.m.</td>
<td></td>
<td>Conclusion and end of the sessions</td>
</tr>
</tbody>
</table>
### SESSION IV – QUANTIFICATION OF CARDIO-METABOLIC RISK IN PATIENTS WITH HYPERURICEMIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 a.m.</td>
<td>Introduction to the meeting objectives</td>
</tr>
<tr>
<td>C. Borghi</td>
<td>(Bologna, IT)</td>
</tr>
</tbody>
</table>
| **Chairpersons:** | G. Mancia (Milan, IT)  
A. J. Manolis (Athens, GR) | 09.00 a.m. | C. Ferri (L’Aquila, IT)  
Is drug-induced hyperuricemia a cardio-metabolic risk factor? | T. R. Merriman (Dunedin, NZ)  
Is genetic approach the right solution? | J. Dawson (Glasgow, UK)  
Is genetic profile useful for clinical practice? | M. Burnier (Lausanne, CH)  
Is the measure of xantino-oxidase a reliable tool? | L. Scheepers (Gothenburg, SE)  
Is it reasonable to consider a functional index? | 10.00 a.m. | General discussion |
| 10.20 a.m. | Coffee break                                                        |

### SESSION V – PREVENTION OF CARDIO-METABOLIC RISK IN PATIENTS WITH HYPERURICEMIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
</tr>
</thead>
</table>
| 11.30 a.m. | E. Lurbe (Valencia, ES)  
Age-dependent prevention of hyperuricemia: the earlier is the better? | D. I. Feig (Birmingham-AL, US)  
The role of fructose consumption and dietary approach | G. Grassi (Milan, IT)  
The management of additional risk factors in patients with hyperuricemia | G. Desideri (L’Aquila, IT)  
Is the determination of serum uric acid enough? | 12.50 p.m. | General discussion |
| 12.30 p.m. | Lunch                                                               |
**SESSION VI – HYPERURICEMIA AND CARDIO-METABOLIC RISK: WHO IS TO TREAT?**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker/Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>02.00 p.m.</td>
<td>S. Taddei (Pisa, IT)</td>
<td>A. J. Manolis (Athens, GR) SGLT-2 inhibitors and control of uric acid: mechanism and potential advantages</td>
</tr>
<tr>
<td>02.20 p.m.</td>
<td>J. George (Dundee, UK)</td>
<td>Urate lowering drugs and prevention of cardiometabolic disease: the evidence</td>
</tr>
<tr>
<td>02.40 p.m.</td>
<td>S. Masi (Pisa, IT)</td>
<td>Recent evidence in cardiorenal protection with Urate Lowering Treatment</td>
</tr>
<tr>
<td>03.00 p.m.</td>
<td>A. Stack (Limerick, IE)</td>
<td>Is there any “J-shaped” curve for serum uric acid?</td>
</tr>
<tr>
<td>03.20 p.m.</td>
<td>C. Borghi (Bologna, IT)</td>
<td>Hyperuricemia and cardiometabolic disease: the role of renal impairment</td>
</tr>
<tr>
<td>03.40 p.m.</td>
<td>A. D. Struthers (Dundee, UK)</td>
<td>The treatment of asymptomatic hyperuricemia: who, when and why</td>
</tr>
<tr>
<td>04.00 p.m.</td>
<td>L. G. Sanchez-Lozada (Mexico City, MX)</td>
<td>The non-pharmacologic approach to hyperuricemia. Solutions beyond diet</td>
</tr>
<tr>
<td>04.20 p.m.</td>
<td>J. T. Kielstein (Braunschweig, DE)</td>
<td>How to investigate the cardiovascular and renal effects of urate-lowering drugs?</td>
</tr>
<tr>
<td>04.40 p.m.</td>
<td></td>
<td>General discussion</td>
</tr>
<tr>
<td>05.10 p.m.</td>
<td></td>
<td>Closing Remarks and end of the Symposium</td>
</tr>
</tbody>
</table>
**MEETING VENUE**
The venue for the Meeting is **Salone del Podestà, Palazzo Re Enzo** - Piazza del Nettuno, 1 - Bologna

**SECRETARIAT DESK DURING THE MEETING**
The secretariat desk is open at the following times:
Tuesday, November 13th, from 08.00 a.m. to 06.00 p.m.
Wednesday, November 14th, from 08.00 a.m. to 05.30 p.m.

**OFFICIAL LANGUAGE**
The official language of the Meeting is English.

**REGISTRATION**
The Meeting is free to attend. The registration link is available on the website [www.iec-srl.it](http://www.iec-srl.it) until November 8th. Onsite registrations can be accepted.

**TECHNICAL FACILITIES SPEAKERS**
Facilities are available for computer presentations and overhead projections.
A slide center with PC (Powerpoint for Windows) is available for check and preview of presentations.
It is essential that speakers take their presentations to the slide center at least one hour before the session starts.
The slide center is open at the following times:
Tuesday, November 13th, from 08.00 a.m. to 06.00 p.m.
Wednesday, November 14th, from 08.00 a.m. to 05.30 p.m.

**LUNCHES AND COFFEE BREAKS**
Lunches and coffee breaks are served in the Congress area.

**ABSTRACTS BOOK**
Participants can get the abstract book at the Symposium.

**CERTIFICATE OF ATTENDANCE**
The certificate of attendance is available, on request, at the end of the Meeting at the secretariat desk.

**CME CREDITS**
EACCME and EBAC Credits have been obtained for physicians for the following disciplines: Cardiology, Internal Medicine, Metabolic and Diabetes Diseases, Nephrology, Rheumatology, Endocrinology, Neurology, Clinical Biochemistry, Hygiene.

**ITALIAN CME CREDITS**
Provider Italian CME Credits: I&C s.r.l. 5387 (event number 240472)
Number of credits: 4,2
I&C s.r.l. is responsible for the content, the quality and the ethical honesty of the CME activity.
The meeting is accredited for the following professions: Nurse, Pharmacist, Biologist, Physician (specialties: Cardiology, Internal Medicine, Metabolic and Diabetes Diseases, Nephrology, Rheumatology, Endocrinology, Neurology, Clinical Biochemistry, Hygiene). The physicians belonging to other specialties will not get the credits.
The attendance to the meeting is partially on sponsor companies invitation.

**METHODOLOGY:** Residential

**COURSE OBJECTIVES:** Clinical, Diagnostic, Therapy, Treatment Path
In order to obtain CME credits, it is mandatory for participants to attend 90% of the course (both days) and to complete CME procedures online: learners’ feedback form and educational needs form. Instructions are provided on site.
EACCME CREDITS

The “URIC ACID AND CARDIOMETABOLIC DISEASE: FROM BENCH TO BEDSIDE”, Bologna, Italy, 13/11/2018-14/11/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 14 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EACCME® credits
Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.

In order to help you issue individual certificates to each participants, please find below the breakdown of ECMEC®s per day:
13.11.2018 - 7,00
14.11.2018 - 7,00
The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.

EBAC CREDITS

The event “URIC ACID AND CARDIOMETABOLIC DISEASE: FROM BENCH TO BEDSIDE” (Ref. 00004467), is accredited by the European Board for Accreditation in Cardiology for 13 CME credit hour(s) [Day #1: 7 CME credit(s) - Day #2: 6 CME credit(s)].

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Enrico Agabiti-Rosei  
Department of Clinical and Experimental Sciences  
University of Brescia  
Spedali Civili di Brescia  
Brescia (Italy)

Michael H. Alderman  
Distinguished University Professor Emeritus  
Departments of Medicine and Population Health  
Albert Einstein College of Medicine  
Bronx, New York-NY (USA)

Ettore Ambrosioni  
Internal Medicine  
University of Bologna (Former Professor)  
Bologna (Italy)

Mariano Andrés  
Department of Rheumatology  
General University Hospital of Alicante  
Miguel Hernández University  
Alicante (Spain)

Claudio Borghi  
Department of Medical and Surgical Sciences (DIMEC)  
Department of Internal Medicine  
Alma Mater Studiorum University of Bologna  
St. Orsola-Malpighi University Hospital  
Bologna (Italy)

Michel Burnier  
Nephrology and Hypertension  
Department of Medicine  
Vaud University Hospital Center  
Lausanne (Switzerland)

Renata Cifkova  
Center of Cardiovascular Prevention  
First Faculty of Medicine  
Charles University, Thomayer Hospital  
Prague (Czech Republic)

Jesse Dawson  
Institute of Cardiovascular and Medical Sciences  
University of Glasgow  
Queen Elizabeth University Hospital  
Glasgow (United Kingdom)

Giovambattista Desideri  
Division of Geriatric Medicine  
University of L’Aquila  
SS Filippo and Nicola Hospital  
Avezzano-L’Aquila (Italy)

Daniel I. Feig  
Division of Nephrology, Pediatrics  
University of Alabama  
Birmingham-AL (USA)

Claudio Ferri  
Division of Internal Medicine and Nephrology  
School of Internal Medicine  
University of L’Aquila  
San Salvatore Hospital  
Coppito - L’Aquila (Italy)

Francesco M. Galassi  
College of Humanities, Arts and Social Sciences  
Flinders University  
Adelaide - SA (Australia)

Jacob George  
Cardiovascular Medicine & Therapeutics  
TASC Research and Development Office  
Tayside Medical Sciences Centre  
University of Dundee, Ninewells Hospital  
Dundee (United Kingdom)

Terence Gibson  
Department Acute Medicine  
Guy’s and St Thomas’ NHS Foundation Trust  
London (United Kingdom)

Michael M. Givertz  
Cardiovascular Division  
Brigham and Women’s Hospital  
Harvard Medical School  
Boston-MA (USA)

Guido Grassi  
Internal Medicine, School of Medicine and Surgery  
University of Milano-Bicocca  
St. Gerardo Hospital, Monza  
Milan (Italy)

Richard J. Johnson  
Division of Renal Diseases and Hypertension  
University of Colorado  
Anschutz Medical Campus  
Aurora-CO (USA)

Duk-Hee Kang  
Department of Internal Medicine  
Division of Nephrology  
Ewha Women’s University  
College of Medicine  
Seoul (Korea)

Jan T. Kielstein  
Nephrology and Rheumatology Department  
Academic Teaching Hospital Braunschweig  
Braunschweig (Germany)
Masanari Kuwabara  
Department of Cardiology  
Toranomon Hospital  
Tokyo (Japan)

Empar Lurbe  
Pediatrics Department  
University of Valencia, Clinical Hospital of Valencia  
Valencia (Spain)

Giuseppe Mancia  
University of Milano-Bicocca  
Milan (Italy)

Athanasios J. Manolis  
Department of Cardiology  
“Asklepieion” General Hospital  
Athens (Greece)

Stefano Masi  
Department of Clinical and Experimental Medicine  
University of Pisa  
Pisa (Italy)

Tony R. Merriman  
Biochemistry Department  
School of Medical Sciences  
University of Otago  
Dunedin (New Zealand)

Maria Lorenza Muiesan  
Internal Medicine, School of Emergency Medicine  
University of Brescia  
Department of Medicine – Spedali Civili of Brescia  
Brescia (Italy)

Krzysztof Narkiewicz  
Department of Hypertension and Diabetology  
Medical University of Gdansk  
Gdansk (Poland)

Peter M. Nilsson  
Lund University  
Department Clinical Sciences  
Skane University Hospital  
Malmo (Sweden)

Paolo Palatini  
Department of Medicine  
University of Padua  
Padua (Italy)

Roberto Pontremoli  
Department of Internal Medicine and Medical Specialties  
University of Genoa  
Genoa (Italy)

Leonardo Punzi  
Rheumatology Unit  
Department of Medicine Medical School  
University of Padua  
Padua (Italy)

Josep Redon  
Department of Internal Medicine  
University of Valencia, Clinical Hospital of Valencia  
Valencia (Spain)

Dietrich Rotenbacher  
Institute of Epidemiology and Medical Biometry  
Ulm University  
Ulm (Germany)

L. Gabriela Sanchez-Lozada  
Department of Nephrology  
National Institute of Cardiology Ignacio Chávez  
Mexico City (Mexico)

Lieke Scheepers  
Biometrics, Early Clinical Development  
IMED Biotech Unit, AstraZeneca  
Gothenburg (Sweden)

Austin Stack  
Department of Nephrology  
University Hospital Limerick & Graduate Entry Medical School University of Limerick  
Limerick (Ireland)

Allan D. Struthers  
Cardiovascular Medicine  
Medical Research Institute  
Division of Molecular and Clinical Medicine  
University of Dundee  
Dundee (United Kingdom)

Stefano Taddei  
Department of Internal Medicine  
University of Pisa  
Pisa (Italy)

Konstantinos Tsioufis  
First Cardiology Clinic, Medical School  
National and Kapodistrian University of Athens  
Hippokration Hospital  
Athens (Greece)

Agostino Virdis  
Department of Clinical and Experimental Medicine  
University of Pisa  
Pisa (Italy)

Sasiwarang Goya Wannamethee  
Primary Care and Population Health  
UCL Medical School  
London (United Kingdom)